An immune-monitoring assay measuring peripheral T-cell responses against carcinoembryonic antigen can predict clinical outcomes in colorectal cancer patients receiving anti-PD-1 therapy, according to a study published in Cancer Immunology, Immunotherapy. The investigators demonstrated that quantifying circulating CEA-specific CD8-positive T-cell activity provides valuable predictive insight into both objective tumor response and 12-month progression-free survival among patients with mismatch repair-deficient or microsatellite instability-high tumors.
Assessment of CEA-specific T-cell responses has long been considered a potentially clinically relevant approach for predicting treatment response and prognosis in colorectal cancer. However, the successful clinical translation of this monitoring strategy has previously been hindered by incomplete epitope mapping across the protein and a critical lack of standardized, broadly applicable immune-monitoring assays for clinical practice.
To overcome these clinical barriers, the authors systematically screened CD8-positive T-cell epitopes located within CEA. Their comprehensive discovery procedure integrated in silico computational prediction, co-culture experiments utilizing peptides and peripheral blood mononuclear cells, competitive binding assays, and immunizations performed in human leukocyte antigen-transgenic mouse models to confirm immune activation.
Through these multi-step screening efforts, the researchers validated 59 immunogenic CD8-positive T-cell epitopes restricted across 13 HLA-A, 15 HLA-B, and 14 HLA-C allotypes. These identified allotypes collectively cover more than 90 percent, 70 percent, and 90 percent of Northeast Asian populations, respectively, ensuring wide potential population applicability for the mapped targets.
Using the validated epitopes, the study established an interferon-gamma enzyme-linked immunospot assay to quantify circulating CEA-specific T-cell responses. The team then evaluated patients with dMMR and MSI-H colorectal cancer receiving anti-PD-1 therapy, assessing a derivation cohort of 80 patients alongside an independent test cohort of 21 patients, with objective response and 12-month progression-free survival serving as clinical endpoints.
In the derivation cohort, the post-treatment to pre-treatment CEA-specific T-cell fold change reliably predicted objective response with an area under the curve of 0.866 at a cut-off of 2.15, as well as 12-month progression-free survival with an area under the curve of 0.851 at a cut-off of 2.05. This cellular fold metric outperformed conventional markers, including KRAS and BRAF mutation status and early declines in serum CEA levels.
Based on these derivation findings, investigators predefined a unified fold cut-off of 2.1 for subsequent prospective validation in the independent cohort. In that 21-patient test group, the assay retained solid predictive efficacy, demonstrating area under the curve values of 0.809 for objective response and 0.824 for 12-month progression-free survival. The authors concluded that this peripheral blood readout serves as a clinically informative biomarker for stratifying response and progression-free survival following anti-PD-1 therapy in dMMR and MSI-H colorectal cancer.
Subject of Research: Peripheral CEA-specific T-cell responses as predictive biomarkers for anti-PD-1 therapy in colorectal cancer
Article Title: Peripheral CEA-specific T-cell responses predict anti-PD-1 outcomes in dMMR/MSI-H colorectal cancer
Article References: Zhu, S., Liu, W., Fu, H., Zhang, X., & Shen, C. (2026). Peripheral CEA-specific T-cell responses predict anti-PD-1 outcomes in dMMR/MSI-H colorectal cancer. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-026-04633-3
Image Credits: AI Generated
DOI: 10.1007/s00262-026-04633-3
Keywords: CEA-specific T cells, anti-PD-1 therapy, colorectal cancer, dMMR, MSI-H, IFN-γ ELISpot, CD8+ T-cell epitopes, carcinoembryonic antigen, immune monitoring, progression-free survival, objective response, HLA allotypes, peripheral blood biomarker, immunotherapy stratification, KRAS mutation, BRAF mutation
News Source: Nathaniel Bowman. (November 18, 2026). Peripheral CEA-Specific T-Cell Changes Predict Colorectal Cancer Immunotherapy Outcomes. Scienmag.



